

Table 1: Baseline data of the study population

	Treatment group (N = 30)	Placebo group (N = 30)	P. Value
Age (Years)	52.2 ± 4.33	52.5 ± 5	0.8048
Duration of ED (months)	12.87 ± 4.04	11.8 ± 3.6	0.28507
Co-morbidities			
DM	10 (33.33%)	7 (23.33%)	0.3900
HTN	7 (23.33%)	4 (13.33%)	0.32511
Dyslipidemia	4 (13.33%)	2 (6.67%)	0.39801
HbA1C	5.6 ± 0.79	5.38 ± 0.66	0.2466
IIEF (Pre)	15.97 ± 1.38	15.73 ± 1.72	0.5642
PSV	41.67 ± 7.6	42.67 ± 9.91	0.6626
EDV	10.6 ± 3.06	10.5 ± 3.79	0.9109

Table 2: Efficacy of treatment

	Treatment group (N = 30)	Placebo group (N = 30)	P. Value
1 month			
IIEF	16.12 ± 1.25	15.99 ± 1.21	0.6838
PSV (ml/sec)	42.21 ± 7.3	44.47 ± 7.59	0.2446
EDV (ml/sec)	9.9 ± 2.71	9.83 ± 3.32	0.93241
Likert Score	1.63±0.70	1.56±0.66	0.6917
3 months			

IIEF	16.44 ± 1.17	16.31 ± 1.06	0.6537
PSV (ml/sec)	43.13 ± 8.56	46.5 ± 8.5	0.1314
EDV (ml/sec)	9.07 ± 2.55	8.77 ± 2.9	0.6716
Likert Score	1.46 ± 0.49	1.33 ± 0.47	0.2987
6 months			
IIEF	16.35 ± 1.45	16.23 ± 1.19	0.7273
PSV (ml/sec)	43.8 ± 8.76	46.3 ± 7.8	0.24801
EDV (ml/sec)	9.7 ± 2.61	9.07 ± 2.89	0.37693
Likert Score	1.43 ± 0.49	1.4 ± 0.48	0.8115